Device field safety notices pile up across UK, Germany and Canada: a QA checklist

What happened

On 10 November 2026 the MHRA published its weekly list of Field Safety Notices (FSNs). It covers about two dozen device manufacturers, and the entries named include Abiomed, Dexcom, Medtronic and Siemens. The records show a quirk: the list's title and its description give different months. The page address refers to 2 to 6 November 2026. Teams should confirm the covered dates at source before logging the list as reviewed.

The same day, Germany's BfArM posted three urgent field safety notices: Boston Scientific's Vercise Neural Navigator 5 software for deep brain stimulation programming; Shockwave Medical's Shockwave Reducer; and Bolton Medical's TREO, RelayPro and RelayPlus aortic stent-graft systems. Health Canada listed two recalls: a Type II recall of two Accell Connexus lots from IsoTis OrthoBiologics, and a Class II recall of Datex-Ohmeda Carestation 850 and 850c anaesthesia systems.

What the public entries do and do not say

The public detail varies widely. The BfArM entry for the Vercise software gives no detail on the issue or the required actions. For the Shockwave Reducer, the nature of the problem sits only in the attached Advisory Notice. The Bolton Medical posting likewise points to the manufacturer's Advisory Notice. The MHRA list names manufacturers but, in the record available to us, does not describe the underlying problems. Nothing in these records says what is wrong with the named products from those manufacturers, and we do not speculate.

The Health Canada notices are more specific. IsoTis is voluntarily removing certain Accell Connexus lots after possible particulate contamination, linked to contact between a ball spring and the mixing container during manufacture. Carestation 850 and 850c systems can deliver a lower concentration of anaesthetic agent than intended. The records do not say how many lots or units are affected, or what corrective action is required.

Why it matters for quality and compliance

An FSN is a manufacturer's communication to users about a safety-related field action. Regulators publish or list them, but the operative instructions usually sit in the manufacturer's own notice. That creates a gap. A regulator's web entry can be a pointer rather than a complete record, and a team that relies on the headline alone may miss the required action.

Two points stand out. First, the manufacturing-linked Accell Connexus recall shows how a process-level contact point, here a spring touching a mixing container, can lead to a market action. Second, the Carestation entry shows that a performance deviation, delivering less agent than intended, is handled as a recall. Both are reminders that complaint trending, change control and equipment qualification feed directly into field action risk.

The MHRA date discrepancy is a document-control issue as well. If a surveillance log records the wrong week, a notice can be missed or an acknowledgement deadline can be mis-set.

Who is affected

The most directly affected are hospitals, device distributors, importers and authorised representatives that hold the named products, along with the manufacturers themselves. The BfArM entries involve neurostimulation software, a cardiovascular device and aortic stent-graft systems. The Health Canada entries involve an orthobiologic product and anaesthesia equipment. Which customers, lots or software versions are in scope is not stated in the public records and must be taken from each manufacturer's notice.

Companies working across regions should note that the same day produced actions in three jurisdictions. The records do not show whether any of these actions are linked to one another, so teams should not assume equivalence between a German notice and a Canadian recall.

Wider compliance context on the same day

Other regulatory news from 10 November touches different parts of the compliance remit. AIFA published a document on how bibliographic sources should be referenced in promotional materials for medicines. ANSM issued a temporary recommendation allowing pharmacists to substitute Rifinah with two single-agent TB medicines, after Sanofi production problems disrupted European supplies of the rifampicin/isoniazid combination, and it has capped distribution. The US Department of Justice said a Queens adult day care director pleaded guilty to conspiracy to commit health care fraud and money laundering in a $127m Medicare and Medicaid scheme. These are separate matters and the records do not link them to the device notices. Together they show enforcement and supply-continuity attention across several fronts.

What to watch

Watch for the full Advisory Notices behind the BfArM entries, and for any correction to the MHRA list's date labelling. For the Canadian recalls, watch for further detail on affected lots and systems. Any follow-up from other regulators for the same products is not yet known.